Reassessment of buprenorphine in conditioned place preference: Temporal and pharmacological considerations

Psychopharmacology

Volumn 172, Issue 1, 2004, Pages 58-67

  Tzschentke, Thomas M ^a  

^a GRÜNENTHAL GMBH   (Germany)

Author keywords

Abuse; Addiction; Opioid receptors; Reward; Sensitization

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; BUPRENORPHINE; DRUG VEHICLE; HALOPERIDOL; NALOXONE; NALOXONE BENZOYLHYDRAZONE; NALTRINDOLE; NOCICEPTIN RECEPTOR ANTAGONIST; NORBINALTORPHIMINE;

ANIMAL EXPERIMENT; ARTICLE; CONDITIONING; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MEGADOSE; DRUG SCREENING; EXPERIMENT; KINETICS; LOCOMOTION; MALE; NONHUMAN; OUTCOMES RESEARCH; PLACE PREFERENCE; PRIORITY JOURNAL; RAT; REPRODUCIBILITY; SENSITIZATION; STANDARD; TIME;

ANIMALS; BUPRENORPHINE; CONDITIONING, OPERANT; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MOTOR ACTIVITY; NALOXONE; NALTREXONE; NARCOTICS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID; RECEPTORS, OPIOID, KAPPA; TIME FACTORS;

EID: 1542284242     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-003-1626-4     Document Type: Article

References (59)

1. 14C]-2- deoxyglucose study. Brain Res. 478:326-336
2. Amass L, Kamien JB, Mikulich SK (2001) Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. Drug Alcohol Depend 61:173-181
3. Anon (2001) Editorial. Drugs Future 26:896-897
4. Bickel WK, Amass L (1995) Buprenorphine treatment of opioid dependence: a review. Exp Clin Psychopharmacol 3:477-489
5. Bloms-Funke P, Gillen C, Schuettler AJ, Wnendt S (2000) Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor. Peptides 21:1141-1146
6. Boas R, Villiger J (1985) Clinical actions of fentanyl and buprenorphine. Br J Anaesth 57:192-196
7. Brookoff D (1993) Abuse potential of various opioid medications. J Gen Int Med 8:688-690
8. Brown EE, Finlay JM, Wong JTF, Damsma G, Fibiger HC (1991) Behavioral and neurochemical interactions between cocaine and buprenorphine: implications for the pharmacotherapy of cocaine abuse. J Pharmacol Exp Ther 256:119-126
9. 63Ni electron-capture gas chromatographic assay for buprenorphine and metabolites in human urine and feces. J Chromatogr 337:291-300
10. Cowan A, Lewis JW (eds) (1995) Buprenorphine: combatting drug abuse with a unique opioid. Wiley-Liss, New York
11. Cowan A, Lewis JW, MacFarlane IR (1977) Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 60:537-545
12. Dum JE, Herz A (1981) In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions. Br J Pharmacol 74:627-633
13. Dykstra LA (1983) Behavioral effects of buprenorphine and diprenorphine under a multiple schedule of food presentation in squirrel monkeys. J Pharmacol Exp Ther 226:317-323
14. Endoh T, Matsuura H, Tanaka C, Nagase H (1992) Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo. Arch Int Pharmacodyn Ther 316:30-42
15. Foltin RW, Fischman MW (1994) Effects of buprenorphine on the self-administration of cocaine by humans. Behav Pharmacol 5:79-89
16. France CP, Jacobson AE, Woods JH (1984) Discriminative stimulus effects of reversible and irreversible opiate agonists: morphine, oxymorphazone and buprenorphine. J Pharmacol Exp Ther 230:652-657
17. Fudala PJ, Iwamoto ET (1990) Conditioned aversion after delay conditioning with amphetamine. Pharmacol Biochem Behav 35:89-92
18. Gaiardi M, Bartoletti M, Bacchi A, Gubellini C, Babbini M (1997) Motivational properties of buprenorphine as assessed by place and taste conditioning in rats. Psychopharmacology 130:104-108
19. Griffiths RR, McLeod DR, Bigelow GE, Liebson IA, Roache JD (1984) Relative abuse liability of diazepam and oxazepam: behavioral and subjective dose effects. Psychopharmacology 84:147-154
20. Gysling K, Wang RY (1983) Morphine-induced activation of A10 dopamine neurons in the rat. Brain Res 277:119-127
21. Hambrook JM, Rance MJ (1976) The interaction of buprenorphine with the opiate receptor: lipophilicity as a determining factor in drug-receptor kinetics. In: Kosterlitz HW (ed) Opiates and endogenous opioid peptides. Elsevier, Amsterdam, pp 295-301
22. Hand TH, Stinus L, Le Moal M (1989) Differential mechanisms in the acquisition and expression of heroin-induced place preference. Psychopharmacology 98:61-67
23. Huang P, Kehner GB, Cowan A, Liu-Chen LY (2001) Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 297:688-695
24. Jasinski DR, Pevnick JS, Griffith JD (1978) Human pharmacology and abuse potential of the analgesic buprenorphine. Arch Gen Psychiatry 35:501-516
25. Johnson SW, North RA (1992) Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 12:483-488
26. Kalivas PW, Duffy P (1987) Sensitization to repeated morphine injection in the rat: possible involvement of A10 dopamine neurons. J Pharmacol Exp Ther 241:204-212
27. Lattanzi R, Negri L, Giannini E, Schmidhammer H, Schutz J, Improta G (2001). HS-599: a novel long acting opioid analgesic does not induce place-preference in rats. Br J Pharmacol 134:441-447
28. Leander DJ (1987) Buprenorphine has potent kappa opioid receptor antagonist activity. Neuropharmacology 26:1445-1447
29. Leone P, Di Chiara G (1987) Blockade of D-1 receptors by SCH23390 antagonizes morphine-and amphetamine-induced place preference conditioning. Eur J Pharmacol 135:251-254
30. Lewis JW (1985) Buprenorphine. Drug Alcohol Depend 14:363-372
31. Liguori A, Morse WH, Bergman J (1996) Respiratory effects of opioid full and partial agonists in rhesus monkeys. J Pharmacol Exp Ther 277:462-472
32. Marsch LA, Bickel WK, Badger GJ, Rathmell JP, Swedberg MD, Jonzon B, Norsten-Hoog C (2001) Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans. J Pharmacol Exp Ther 299:1056-1065
33. Mucha RF, Herz A (1985) Motivational properties of kappa nd mu opioid receptor agonists studied with place and taste preference conditioning. Psychopharmacology 86:274-280
34. Ohtani M, Shibuya F, Kotaki H, Uchino K, Saitoh Y, Nakagawa F (1989) Quantitative determination of buprenorphine and its active metabolite, norbuprenorphine, in human plasma by gas chromatography-chemical ionization mass sprectrometry. J Chromatogr 487:469-475
35. Ohtani M, Kotaki H, Sawada Y, Iga T (1995) Comparative analysis of buprenorphine-and norbuprenorphine-induced anagesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 272:505-510
36. Ohtani M, Kotaki H, Nishitateno K, Sawada Y, Iga T (1997) Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. J Pharmacol Exp Ther 281:428-433
37. Pchlintsev MV, Gorbacheva EN, Zvartau EE (1991) Simple methodology of assessment of analgesics' addictive potential in mice. Pharmacol Biochem Behav 39:873-876
38. Pontani RB, Vadlamani NL, Misra AL (1985) Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant. Xenobiotica 15:287-297
39. Preston KL, Jasinski DR (1991) Abuse liability studies of opioid agonist-antagonists in humans. Drug Alcohol Depend 28:49-82
40. Rance MJ, Dickens JM (1978) The influence of drug-receptor kinetics on the pharmacological and pharmacokinetic profiles of buprenorphine. In: Van Ree J, Terenius L (eds) Characteristics and functions of opioids. Elsevier/North Holland Biomedical Press, Amsterdam, pp 65-66
41. Rance MJ, Lord JAH, Robinson T (1980) Biphasic dose-response to buprenorphine in the rat tail-flick assay: effect of naloxone pretreatment. In: Way EL (Ed) Endogenous and exogenous opiate agonists and antagonists. Pergamon Press, New York, pp 387-390
42. Richards ML, Sadee W (1985) Buprenorphine is an antagonist at the kappa opioid receptor. Pharmacol Res 2:178-181
43. Rosenbaum JS, Holford NHG (1985) In vivo receptor binding of opioid drugs at the mu site. J Pharmacol Exp Ther 233:735-740
44. Rowlett JK, Gibson TR, Bardo MT (1994) Dissociation of buprenorphine-induced locomotor sensitization and conditioned place preference in rats. Pharmacol Biochem Behav 49:241-245
45. Schulz R, Herz A (1976) The guinea-pig ileum as an in vitro model to analyze dependence liability of narcotic drugs. In: Kosterlitz HW (ed) Opiates and endogenous opioid peptides. Elsevier, Amsterdam, pp 319-326
46. Shippenberg TS, Herz A (1986) Differential effects of mu and kappa opioid systems on motivational processes. NIDA Res Monogr 75:563-566
47. Shuster L, Webster GW, Yu G (1975) Increased running response to morphine in morphine-pretreated mice. J Pharmacol Exp Ther 192:64-67
48. Stoller KB, Bigelow GE, Walsh SL, Strain EC (2001) Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology 154:230-242
49. Strain EC, Stitzer ML, Liebson IA, Bigelow GE (1994) Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry 151:1025-1030
50. Tzschentke TM (1998) Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog Neurobiol 56:613-672
51. Tzschentke TM (2001) Buprenorphine in conditioned place preference studies in the rat. Soc Neurosci Abstr 27:647.18
52. Tzschentke TM (2002) Behavioral pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction. Psychopharmacology 161:1-16
53. Tzschentke TM, Bruckmann W (2002) Temporal and pharmacological determinants of buprenorphine conditioned place preference. Behav Pharmacol 13:507
54. Villiger J, Taylor K (1981) Buprenorphine: characteristics of binding sites in the rat central nervous system. Life Sci 29:2699-2708
55. Wall A, Hinson RE, Schmidt E, Johnston C, Streather A (1990) Place conditioning with d-amphetamine: the effect of the CS-UCS interval and evidence of a place avoidance. Anim Learn Behav 18:393-400
56. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE (1994) Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 55:569-580
57. Walter DS, Inturrisi CE (1995) Absorption, distribution, metabolism, and excretion of buprenorphine in animals and humans. In: Cowan A, Lewis JW (eds) Buprenorphine: combatting drug abuse with a unique opioid. Wiley-Liss, New York, pp 113-135
58. Wilding IR, Davis SS, Rimoy GH, Rubin P, Kurihara-Bergstrom T, Tipnis V, Berner B, Nightingale J (1996) Pharmacokinetic evaluation of transdermal buprenorphine in man. Int J Pharm 132:81-87
59. Zaveri N, Polgar WE, Olsen CM, Kelson AB, Grundt P, Lewis JW, Toll L (2001) Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors. Eur J Pharmacol 428:29-36